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MrgA1 and MrgC11 belong to a recently identified family of orphan
G-protein coupled receptors, called mrgs (mas-related genes). They
are only expressed in a specific subset of sensory neurons that are
known to detect painful stimuli. However, the precise physiological
function of Mrg receptors and their underlying mechanisms of signal
transduction are not known. We therefore have screened a series of
neuropeptides against human embryonic kidney (HEK) 293 cells that
stably express either MrgA1 or MrgC11 to identify ligands andor
agonists. MrgA1- or MrgC11-specific agonists stimulated dose-depen-
dent increases in intracellular free Ca2 in a pertussis toxin-insensitive
manner, but failed to alter basal or forskolin-stimulated levels of
intracellular cAMP. Furthermore, studies using embryonic fibroblasts
derived from various G protein knockout mice demonstrated that
both the MrgA1 and MrgC11 receptors are coupled to the Gq/11
signaling pathway. Screening of neuropeptides identified surrogate
agonists, most of these peptides included a common C-terminal
-RF(Y)G or -RF(Y) amide motif. Structure-function studies suggest that
endogenous ligands of Mrg receptors are likely to be RF(Y)G andor
RF(Y) amide-related peptides and that postprocessing of these pep-
tides may serve to determine Mrg receptor-ligand specificity. The
differences in ligand specificity also suggest functional diversity
amongst the Mrg receptors.
G protein-coupled receptors (GPCRs) constitute the largestfamily of cell surface receptors (1, 2). Agonist binding to
GPCRs initiates an intracellular signaling pathway. Subsequent
effectors are activated through heterotrimeric G proteins com-
prised of , , and  subunits, leading to an appropriate
physiological response.
Over the last decade, cloning and genome sequencing efforts
have revealed the existence of hundreds of orphan GPCRs.
Many of them are presumably receptors for as yet unidentified
biologically active substances such as hormones and neuropep-
tides. Thus, the identification of an endogenous ligand for an
orphan GPCR may reveal new signaling pathways and signaling
substances. We have recently reported the identification of a
novel family of orphan GPCRs, called mrgs (mas-related genes)
in mice and humans (3). This family can be divided into three
major homology groups (MrgA, MrgB, and MrgC) and is
comprised of 32 murine and 4 human genes (hMrgX1–hMrgX4)
with intact coding sequences, and additional related pseudo-
genes (4). Some Mrg receptors (17 MrgAs and MrgD) are
particularly intriguing because their expression is restricted to
specific subsets of sensory neurons that detect painful stimuli (3).
Moreover, we found that some of these receptors, such as
MrgA1, MrgA4, and MAS1, were distinctively activated by
RF-amide (RFa) neuropeptides, of which the prototypic mem-
ber is the molluscan peptide FMRF-amide (FMRFa) (3).
In general, the FMRFa-related peptides constitute a large family
of neuropeptides that are widely and abundantly distributed in
invertebrates functioning as neurotransmitters and neuromodula-
tors (5, 6). In the genome of Caenorhabditis elegans, more than
20 RFa peptide genes, encoding over 50 distinct RFa peptides, have
been found (6, 7). However, in vertebrates, only a few RFa peptides
have been identified, such as NPFF and NPAF (8, 9), the prolactin-
releasing peptide (10), the two RFRPs (11), the kisspeptin (12), and
1-MSH. Their corresponding receptors have been identified or
deduced by pharmacological techniques or by a mining genome
databases and their functional significance has been well docu-
mented (9–11, 13–17).
A recent study by Lembo et al. (18) showed that human MrgX1
(hMrgX1; SNSR3) is expressed solely in dorsal root ganglia (DRG)
neurons and potently activated by the preproenkephalin products,
in particular, adrenal medulla peptide 22 (BAM-22P). Based on
sequence homology analysis, hMrgX1 is classified as being between
the mouse MrgA and MrgC subfamilies (3). We initially identified
MrgC11 as a member of a subfamily of Mrg pseudogenes (3). In this
work, we found that MrgC11 has an intact coding sequence and is
expressed in a specific subpopulation of nociceptor neurons in the
DRG. To address the questions of the ligand selectivity of these
receptors and the mechanism of coupling to cellular signaling, we
established human embryonic kidney (HEK) 293 cells stably ex-
pressing either MrgA1 or MrgC11 and have screened neuropep-
tides to identify ligands andor agonists. We have investigated
signal transduction events in terms of calcium signaling and G
coupling specificity. In addition, we investigated the structural
requirements for agonists by examining structure–activity relation-
ships. These studies will facilitate the eventual identification of the
natural ligands and physiological roles for a subset of these Mrg
receptors and help clarify the function of these receptors.
Materials and Methods
Materials. Wild type and G knockout (KO) mouse embryonic
fibroblasts (MEFs) were prepared and cultured from embryonic
day 8.5 to 9.5 embryos as described (19). HEK293 and G KO
MEFs were cultured in DMEM10% FBS. U73122, U73343, and
thapsigargin (TG) were purchased from Calbiochem. Fura-2AM
was purchased from Molecular Probes. All other reagents were
purchased from Sigma.
Cloning and Expression of the MrgC11 Receptor. Nonisotopic in situ
hybridization on frozen sections was performed as described by us-
ing cRNA probes (3). For double labeling with Griffonia
simplicifolia IB4 lectin, sections were incubated with 12.5 gml
FITC-conjugated IB4 lectin (Sigma) after in situ hybridization. The
full-length cDNA-encoding MrgC11 was cloned from a newborn
(P0) mouse DRG cDNA library.
Cell Culture and Transfection. HEK293 cells were transfected with
cDNA encoding the MrgA1-GFP, mNPFF2-GFP, or MrgC11-GFP
in pcDNA3.1Zeo () plasmid (Invitrogen) using the FuGENE 6
transfection reagent (Roche Molecular Biochemicals). The trans-
fected cells were selected with 400 gml zeocin in DMEM
supplemented with 10% FBS. Each cloned cell was further selected
for membrane localization of receptor–GFP fusion proteins. The
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selected cells were maintained in the same medium supplemented
with 200 gml zeocin. We designated these established stable cell
lines as HEK-MrgA1, HEK-NPFF2, and HEK-MrgC11. Expres-
sion of each receptor was confirmed by Western blotting using an
anti-GFP monoclonal antibody (Santa Cruz Biotechnology).
Intracellular Calcium Release Assay. HEK-MrgA1 or HEK-MrgC11
was plated in 96-black-well plates (Corning) and grown to conflu-
ence. After incubation with Fura-2AM for 20 min, cells were
washed and equilibrated for 20 min with HBSS (Hanks’ balanced
salt solution) assay buffer. The fluorescence emission caused by
intracellular calcium mobilization elicited by agonists was deter-
mined by using a fluorometric imaging plate reader, Flexstation
(Molecular Devices). All peptides were from Phoenix Pharmaceu-
ticals (St. Joseph, MO), Bachem, American Peptide (Sunnyvale,
CA), or Sigma.
Internalization. MrgA1-GFP or MrgC11-GFP stably expressing
HEK293 cells were grown in 35-mm glass-bottomed dishes (Mat-
Tek, Ashland, MA) in DMEM with 10% FBS. After 4- to 6-h serum
starvation, cells were treated with agonists at 37°C for 30 min. Cells
were washed with PBS and fixed with 3.7% paraformaldehyde in
PBS. The subcellular localization of Mrg-GFP was visualized under
a Leica confocal fluorescence microscope with a20 or40 lens.
Peptide Synthesis. The peptides BAM-15, BAM15-amide
(BAM15a), and Dynorphin-14 were synthesized and purified in the
CalTech peptide facility, and peptide identities were confirmed by
mass spectrometry.
cAMP Assay. cAMP was measured by using a radioimmuno assay kit
(Amersham Pharmacia) as described by the manufacturer. HEK-
MrgA1 or HEK-MrgC11 were cultured in 6-well plates coated with
matriGel for16 h at 37°C in growth medium. After 4- to 6-h serum
starvation, cells were stimulated with or without representative
agonists in the presence or absence of 10 M forskolin for 10 min.
The cells were rapidly washed twice with PBS containing 200 M
Ro20-1724 and cAMP was extracted with 2 ml of cold 60% ethanol.
Quantitation of cAMP was then performed by using a [3H] cAMP
displacement assay (20).
Calcium Imaging. Measurement of [Ca2]i, at the individual cell level
was performed as described (3). Briefly, MrgA1-GFP- or MrgC11-
GFP-transfected cells were grown in specialized glass-bottom
dishes (Bioptechs, Butler, PA) and loaded with fura-2AM in
Hepes-buffered saline. By using a dual wavelength spectrofluorom-
eter coupled to an inverted fluorescence microscope, GFP-positive
cells were identified by using an excitation wavelength of 488 nm,
a dichroic 505 nm long-pass filter, and an emitter filter at band pass
of 535 nm (Chroma Technology, Brattleboro, VT). Measurements
of [Ca2]i were performed on individual Mrg-GFP positive cells at
excitation wavelength of 340 and 380 nm and an emission wave-
length of 510 nm.
Fig. 1. Sequence comparisons of mouse MrgA1, MrgC11, and human MrgX1 and expression of MrgC11. (A) Alignment of the amino acid sequence of mouse MrgA1
(mMrgA1), mouse MrgC11 (mMrgC11), and human MrgX1 (hMrgX1). Residues shaded in black are identical in 50% of the proteins and residues shaded in gray
indicate conservative substitutions. The 7 transmembrane domains (TM1–7) are over-lined. (B and C) In situ hybridization with cRNA riboprobes detecting mMrgC11
innewborn(B)andadult (C)DRGneurons. (D)Double label insituwithmMrgC11probe(red)andstainingwithfluorescent lectin IB4(green) inadultmouseDRGneuron.









Cloning and Expression Analysis of MrgC11. We suggested that all of
the mouse MrgC genes were nonfunctional pseudogenes based on
the draft mouse genomic sequence data that was initially available
(3). To determine whether any of the MrgC genes were indeed
expressed in DRG neurons, we designed degenerate PCR primers
specific for all members of the MrgC subfamily. After PCR
amplification from a newborn (P0) DRG cDNA library, we iden-
tified sequences corresponding to MrgC11. No other MrgC gene
products were identified, suggesting that MrgC11 is the only
expressed MrgC gene in the mouse.
Next, a full-length MrgC11 cDNA was cloned from the newborn
DRG cDNA library. Contrary to our original prediction that
MrgC11 was a pseudogene, this experimentally verified transcript
contains an intact ORF that is predicted by hydrophobicity analysis
to contain seven transmembrane domains. The MrgC11 protein is
51% and 54% identical to the GPCRs MrgA1 and hMRGX1,
respectively (Fig. 1A).
We confirmed that MrgC11 is expressed in newborn and in adult
DRG neurons by means of in situ hybridization (Fig. 1 B and C).
MrgC11 is coexpressed in the small-diameter nociceptive neurons
that contain IB-4 binding sites (Fig. 1D). Recently, the rat ortholog
of MrgC11 was cloned and named Sensory Neuron-Specific GPCR
Receptor (SNSR) because of its exclusive expression in small-
diameter, IB-4-positive nociceptive neurons (18). Taken together,
these data indicate that MrgC11 codes for a potentially functional
GPCR in nociceptive neurons.
FLRFa and 2-MSH Elicit Transient Intracellular Calcium Responses in
a Receptor-Specific Manner. We tested a variety of compounds in the
ligand screen to determine whether they act as agonists and elicit
receptor specific calcium responses in HEK-MrgA1 and HEK-
MrgC11 cells. We used FLRFa or 2-MSH to activate MrgA1 and
MrgC11, respectively because these are the most potent agonists
amongst the peptides tested for each receptor (see Table 1).
Pretreatment of the cells for 10 min with a specific phospholipase
C inhibitor, 10 M U73122 completely inhibited the 3 M FLRFa-
or 1 M 2-MSH-induced calcium release (Fig. 2 A and D). In
contrast, pretreatment of cells with 10 M U73343 (an inactive
analogue of U73122) did not significantly affect [Ca2]i responses
for both receptors (Fig. 2 A and D).
To determine whether Ca2 influx occurs from the extracellular
medium, FLRFa- or 2-MSH-induced [Ca2]i responses were
examined in the presence of 2 mM EGTA (Fig. 2 B and E). In the
presence of EGTA, the agonist-induced calcium responses were
similar in amplitude to the responses obtained in medium contain-
ing the normal level of calcium (Fig. 2 B and E). However, the
response rapidly returned to basal levels, suggesting that in the
absence of EGTA, Ca2 influx occurred (Fig. 2 B and E). Next, we
determined the calcium source responsible for the initial peak in
[Ca2]i by depleting internal calcium stores by the application of 1
M TG (Fig. 2 C and F). When HEK-MrgA1 or HEK-MrgC11 cells
were treated with 1 M TG, the resultant emptying of intracellular
calcium stores blocked the response to FLRFa or 2-MSH (Fig. 2
C and F). These data suggest that FLRFa or 2-MSH can trigger
the mobilization of calcium from IP3-dependent internal calcium
stores, and the resultant intracellular calcium can induce the influx
of extracellular calcium.
Internalization of MrgA1 and MrgC11. We next assessed whether the
agonists can induce the internalization of MrgA1 or MrgC11.
Receptor internalization is a response of GPCRs to ligand stimu-
lation. This process indicates that agonist interacts directly with its
cognate receptor. In nonstimulated conditions, MrgA1-GFP or
MrgC11-GFP fusion proteins were expressed predominantly at the
plasma membrane (Fig. 3 A and C). Stimulation of FLRFa or
2-MSH induced internalization of MrgA1-GFP (Fig. 3B) or
MrgC11-GFP (Fig. 3D) in 90% of cells at 37°C. However, rapid
internalization was not observed at room temperature under the
same conditions (data not shown).
MrgA1 and MrgC11 Coupling to Heterotrimeric G Proteins. Previously,
we reported that transiently overexpressed MrgA1 responded to
FLRFa with high potency (EC50  20 nM) in HEK293 cells
expressing G15. We reexamined the dose dependence in HEK293
cells stably expressing MrgA1 (HEK-MrgA1) but not expressing
exogenous G15. FLRFa stimulated an increase in [Ca2]i with an
EC50 of 402  21 nM in this cellular system (Fig. 4A). The
difference in EC50 value is possibly derived from a variety of sources
such as different coupling efficiencies, different expression levels of
receptor, andor different cellular environment (21). Nonetheless,
the relative ligand selectivity (FLRFa vs. NPFF) was conserved in
both cellular systems.
Heterotrimeric G proteins of the Gi and Gq class are involved
in the propagation of signals from GPCRs leading to [Ca2]i
elevation (22). To determine whether Gi/o proteins are involved in
the [Ca2]i response, we pretreated HEK-MrgA1 or HEK-MrgC11
cells with PTX (100 ngml) for 16 h. PTX blocks responses
mediated by the Gi/o system of G protein transducers but does not
effect signals transmitted through Gs, G12/13, or the Gq/11 family.
The dose dependency in [Ca2]i responses for both receptors were
not affected by PTX (Fig. 4 A and D). In contrast, PTX completely
blocked FLRFa-induced calcium response in HEK-mNPFF2 cells
(data not shown).
We used MEF cell lines derived from Gq/11 or G12/13 double
gene KO mice to test whether activation of MrgA1 or MrgC11
receptors can mobilize calcium responses through the direct par-
ticipation of Gq/11. The Gq/11 KO MEFs or G12/13 KO MEFs
were transfected with cDNAs encoding either MrgA1-GFP or
MrgC11-GFP receptor, and the ability of agonists to increase
[Ca2]i, was measured in individual cells. The GFP receptor fusion
Table 1. The EC50 values (in nM) of various peptides for
HEK-MrgA1 and HEK-MrgC11 cells using FLEXstation assay
Peptides Sequences MrgC11 MrgA1
AnthoRF-
amide
pEGRFa 16  6 Inactive
AF-2 KHEYLRFa 130  24 Inactive
ACEP-1 SGQSWRPQGRFa 46  12 Inactive
FLRF-amide FLRFa 157  12 402  21
FMRF-amide FMRFa 114  32 420  71
FMRF-OH FMRF 544  117 8,204  458
Met-ENK-RF-
amide
YGGFMRFa 133  20 5,252  1,280
Met-Enk-RF YGGFMRF 545  19 Inactive
1-MSH YVMGHFRWDRFa 17  3 Inactive
2-MSH YVMGHFRWDRFG 11  5 Inactive
BAM3200 YGGFMRRVGRPEWWMDYQKRYGGFL 300  124 10,000
BAM-22P YGGFMRRVGRPEWWMDYQKRYG 26  10 2,542  654
BAM-15 VGRPEWWMDYQKRYG 53  2 23,326  1,866
BAM-15-
amide
VGRPEWWMDYQKRYa 479  14 8,773  493
Dynnorphin-
14
IRPKLKWDNQKRYG 22  1 Inactive
PrRP-20 TPDINPAWYTGRGIRPVGRFa 144  18 Inactive
Kiss(107–121) KDLPNYNWNSFGLRFa 102  24 Inactive
Kiss(112–121) YNWNSFGLRFa 50  4 Inactive
PQRF-amide PQRFa 126  28 10,000
NPFF FLFQPQRFa 54  5 2,145  245
NPAF AGEGLNSQFWSLAAPQRFa 282  30 Inactive
RFRP-1 MPHSFANLPLRFa 1,245  112 Inactive
RFRP-3 VPNLPQRFa 113  5 Inactive
NPY YPSKPEDMARYYSALRHYINLITRQRYa 237  30 3,486  986
Data represent means SEM from triplicate independent determinations.
Inactive, no activation was detected at concentrations up to 10 M.
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proteins were used to identify positively transfected cells, and
single-cell calcium assays were performed as described in our
previous studies (3). FLRFa or 2-MSH induced robust, transient
calcium responses in G12/13 KO cells expressing MrgA1 or
MrgC11, but Gq/11 double KO MEFs failed to respond to FLRFa
or 2-MSH (Fig. 4 B and E). The calcium responses in Gq/11 KO
cells were rescued when Gq/11 KO cells were cotransfected with
plasmids encoding wild-type Gq and each receptor (Fig. 4 B and
E). These observations demonstrated that Gq/11 proteins are
coupled to both receptors in the calcium-signaling pathway.
It is also possible that these receptors are coupled to the Gi/o or
to the Gs family of heterotrimeric G proteins. Thus, we measured
cAMP production in the presence of various concentrations of
agonists and presence or absence of forskolin. No significant
inhibition or activation was observed in the presence of various
concentrations of FLRFa or 2-MSH (Fig. 4 C and F). Also,
FLRFa and 2-MSH were unable to inhibit forskolin-induced
cAMP accumulation in these cells (Fig. 4 C and F). Taken together,
these results demonstrate that both MrgA1 and MrgC11 are
coupled to Gq/11, but not to Gi/o or Gs, in HEK293 cells. But,
it remains to be determined how this G protein-coupling specificity
is translated in DRG neurons.
Ligand Identification of MrgA1 and MrgC11. To identify putative
ligands for Mrg receptors, we screened HEK-MrgA1 or HEK-
MrgC11 stable cell lines in a calcium-mobilization assay using a
fluorescence-imaging plate reader (FLEXstation). We tested a
panel of known peptides (100 peptides) at various concentrations
and then measured agonist potencies (EC50) for peptides showing
calcium responses. HEK293 parental cells did not respond to
peptides shown in Table 1. 2-MSH was the best agonist for
MrgC11 (EC50  11  5 nM); this neuropeptide is derived from
pro-opiomelanocotin (POMC). However, MrgC11 was not acti-
vated by other POMC-derived peptides such as -MSH, -MSH,
and endorphins (data not shown), which are largely mediated
Fig. 2. Calcium signaling in HEK-MrgA1 (A–C) and HEK-MrgC11 (D–F). Cells loaded with Fura-2AM were stimulated with each agonist, and fluorescence was
recorded. Graphs represent an average plot of [Ca2]i measurements versus time (in s) in a minimum of 8 cells from representative experiments. Individual data points
represent images taken at 0.8-s intervals. (A and D) U73122 (E), the active phospholipase C inhibitor blocked agonist-induced rise in [Ca2]i. However, U73343 (F),
the inactive analogue, did not affect FLRFa or 2-MSH-induced Ca2 mobilization. After a 10-min pretreatment with U73122 and U73343, each agonist was added.
(B and E) Extracellular [Ca2] dependency of Ca2mobilization. Cells were preincubated for 2 min with 2 mM EGTA (E) or normal medium containing 1.2 mM calcium
(F), and then 3 M FLRFa or 1 M 2-MSH were added. (C and F) TG prevents the agonist-evoked increase of [Ca2]i in HEK-MrgA1 (C) and HEK-MrgC11 (F). In the
presence of 2 mM EGTA, TG (1 M final concentration) was added to deplete internal Ca2 store.
Fig. 3. Internalization of MrgA1-GFP (A and B) and MrgC11-GFP (C and D) was
induced by 3 M FLRFa and 1 M 2-MSH, respectively. (A and C) Serum-starved
(4 h) HEK-MrgA1 or HEK-MrgC11 cells. (B and D) HEK-MrgA1 or HEK-MrgC11
were treated with the indicated agonists for 30 min at 37°C. Results are repre-
sentative of three independent experiments, and the arrow indicates the inter-
nalization process.








through melanocortin (MC) receptors. On the other hand, we failed
to find a better agonist than FLRFa against MrgA1.
As shown in Table 1, a common feature of all activating peptides
for MrgA1 and MrgC11 is the presence of RF(Y)G or RF(Y)a at
the C terminus. The invertebrate neuropeptides terminating with
-RP or -RN at the C terminus were inactive for both receptors up
to100 M (data not shown). However, a distinct structure–activity
relationship exists between MrgA1 and MrgC11. All peptides
containing RF(Y)a or RF(Y)G motif at the C terminus were able
to activate MrgC11 with different potencies, but only certain
peptides among them were able to activate MrgA1 (Table 1).
Furthermore, either RFa or RF-OH itself was sufficient to activate
MrgC11 with EC50 460 35 nM and 632 124 nM, respectively,
whereas RFa or its free acid form was not able to activate MrgA1
(Table 2), suggesting that other as yet unknown structural motifs are
required to activate MrgA1 in addition to the RF(Y)a or RF(Y)G
motif at the C terminus. Because the amidation of RFa peptides is
known to be critical for agonist activity on RFa receptors, such as
GPR54 and NPFF receptors (13, 16, 17), we examined how
amidation andor deamidation of RFa peptides affect the func-
tional affinity for both receptors. The free acid form of FMRFa
resulted in about 20-fold decrease in activity for MrgA1. Also, the
deamidated peptide form of YGFMRFa resulted in complete loss
of activity for MrgA1, whereas deamidation rendered the peptides
about only 4- to 5-fold less active for MrgC11 (Table 1). Inversely,
amidation of BAM-15 peptide caused modest increase (2.7-fold) in
activity for MrgA1, whereas it caused a pronounced decrease
(9-fold) for MrgC11.
To better define the agonist specificity required for activation of
both receptors, we examined the significance of the orientation of
the side chains by substituting D-amino acid isomers in each position
(Table 2). The change of arginine (Arg) chirality resulted in
complete loss of agonist activity for both receptors, suggesting that
Arg-3 is a common critical residue (Table 2). Replacement of the
Met-2 residue by the D-isomer resulted in a 3-fold decrease in
activity for MrgA1, whereas the change resulted in 10-fold increase
in activity for MrgC11 (Table 2). This increase might be attributable
to an optimization of tertiary structure for better receptor binding.
Also, substitution of the Phe-4 with the D-isomer rendered the
peptide inactive for MrgC11, whereas it resulted in only slight
decrease in activity for MrgA1. These data provide further evidence
of structure–activity differences between MrgA1 and MrgC11,
though both receptors are activated by RF-amide-related peptides.
Discussion
We have further defined the G coupling specificity of the Mrg
receptors in heterologus cellular systems. By functional and genetic
Fig. 4. Heterotrimeric G protein coupling of MrgA1 and MrgC11. (A and D) FLRFa or 2-MSH dose-dependently stimulates intracellular calcium mobilization in
HEK-MrgA1 or HEK-MrgC11 in the absence (F) or presence () of PTX (16 h, 100 ngml). All results shown are the mean of triplicate determination SEM. (B and E)
Effect of G subunit KO on [Ca2]i mobilization. KO MEFs were derived from KO mice at embryonic 8.5 and 9.5 days. G12/13 KO MEF (Œ) and Gq/11 KO MEF (E) were
transfected with the cDNAs encoding the MrgA1-GFP (B) or the MrgC11-GFP (E). FLRFa or 2-MSH evoked [Ca2]i responses were completely ablogated in Gq/11 KO
MEF expressing MrgA1-GFP (B) or MrgC11-GFP (E). However, cotransfection (‚) of wild-type Gq plus MrgA1-GFP or MrgC11-GFP in Gq/11 double KO MEF restored
responsiveness to FLRFa or2-MSH, respectively. Positively transfected cells were selected by their green fluorescence excited at 480 nm (GFP-positive cells). On the same
field, cells that did not express GFP (GFP-negative cells) were selected as internal control. (C and F) cAMP production in HEK-MrgA1 (C) or HEK-MrgC11 (F). Cells were
stimulated with various concentrations of FLRFa or2-MSH in the presence or absence of 10M forskolin as described in Materials and Methods. Each value represents
the mean SEM for three independent experiments.
Table 2. The EC50 values of FMRFa peptides chirally modified in
successive single residues for HEK-MrgC11 and HEK-MrgA1 cells
Peptides MrgC11, nM MrgA1, nM
F-M-R-Fa 114  32 420  71
(D)F-M-R-Fa 108  1 882  55
F-(D)M-R-Fa 11  4 1,260  223
F-M-(D)R-Fa Inactive Inactive
F-M-R-(D)Fa Inactive 643  80
R-Fa 460  35 Inactive
R-F-OH 632  124 Inactive
Data represent mean  SEM from triplicate independent determinations.
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studies, we demonstrated that both MrgA1 and MrgC11 are
coupled to Gq/11, but not to Gi/o or Gs signaling pathway. It is
known that activation of hMrgX1 elicited calcium release in a PTX
insensitive manner (18). This finding suggests that the main mode
of signaling of Mrg receptors may be through Gq/11 signaling
pathway. However, the functional significance of the Gq/11 path-
way in DRG neurons has not been well characterized. Recently, D.
Julius and coworkers (23) showed that the activation of the Gq/11
coupled pathway modulates the ability of VR1 (TRPV1), which
detects noxious heat or capsaicin in sensory neurons. VR1 belongs
to the TRP superfamily that includes 20 related cation channels
that play critical roles in processes ranging from sensory physiology
to vasorelaxation and male fertility (24). Some of them, such as
TRPV1, TRPV2, and TRPM8, are expressed in DRG neurons (24).
Thus, it is conceivable that Mrg receptors may regulate the activa-
tion of a specific TRP channel, though Gq/11 signaling pathway to
modulate pain sensitivity.
Recently, Lembo and colleagues (18) proposed that BAM-22P or
BAM-15 derived from preproenkephalin is the endogenous ligand
for hMrgX1 (SNSR3). The human MrgX1 sequence appears most
similar to the murine MrgAs and MrgC11 sequence, though it is not
possible to define clear orthologous pairs (3). BAM-22P and
BAM-15, weakly activate MrgA1, EC50  2.5 M and 23 M,
respectively. MrgC11 is potently activated by verterbrate neuropep-
tides in the following order: 2-MSH (EC50  11 nM)  1-MSH
(EC50  17 nM) BAM-22P (EC50  26 nM) Dynorphin14
BAM-15 (EC50  53 nM), NPFF and Kiss (112–121). Under
physiological conditions, it is not clear which peptide specifically
acts as ligand for the MrgC11 receptor. Precise localization studies
of receptors and peptides will be required to identify endogenous
ligands.
MrgC11 is shown to be activated by all invertebrate and verte-
brate neuropeptides terminating with either RF(Y)G or RF(Y)a.
Previously, we found that specific RFa peptides, FLRFa, NPAF,
and NPFF distinctively activate MrgA1, MrgA4, and MAS1, re-
spectively, in HEK293-G15 cells (3). These results, together with
the high degree of sequence homology between Mrg receptors,
suggest that the cognate ligands for Mrg receptors may also
terminate with the sequence RF(Y)G or RF(Y)a. We further
demonstrated that the C-terminal Arg is a common critical residue
for activation of both MrgA1 and MrgC11 (see Table 2). It is not
surprising that the phenylalanine residue of -RFa can be replaced
by tyrosine because they have very similar configuration and
because of the functional similarity of the aromatic benzene (25).
For example, human kisspeptin (12) ends with RFa, but the murine
and rat homologues apparently end with RYa. In most cases, the
glycine residue at the C terminus appears to act as amide donor. It
is relatively common to find the partially processed peptide with the
whole glycyl residue instead of the amide. Thus, RFa-related
peptides could include peptides ending with -RFG, -RYG, -RFa,
or -RYa.
However, ligand specificity for MrgA1 and MrgC11 was clearly
different even though they are commonly activated by RFa-related
peptides. The difference in ligand specificity can be summarized by
the following observations. First, amidation andor deamination of
agonists differentially acts on activation of both Mrg receptors (see
Table 1). Second, both MrgA1 and MrgC11 showed a different
pattern of specificity for alternative chiral forms of the amino acid
components of the ligand except for Arg residue (see Table 2).
Moreover, the N-terminal sequences of agonists appeared to be
very important for MrgA1 activation. It has been known that
C-terminally amidated peptides can take a variety of conformations
depending on the amino acids at the N terminus (26). Thus,
assuming that the ligand for the Mrg family is a RFa-related
peptide, the combination of amidation and N-terminal sequences
may be sufficient to generate differences in ligand conformation
unique for each Mrg receptor.
In summary, we have determined that MrgC11 is specifically
expressed in a subset of nociceptive neurons in the DRG. We have
also found that both MrgA1 and MrgC11 can be activated by
RFa-related peptides through coupling to the Gq/11 signaling
pathway. Furthermore, we found differences in ligand specificity
between MrgA1 and MrgC11, suggesting functional diversity of
Mrg receptors. Most recently, adenine was proposed as an endog-
enous ligand for rat MrgA (27). However, we could not find any
response of mouse MrgA1, MrgC11, and human MrgX1–MrgX4 to
adenine (data not shown).
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